Nonalcoholic Steatohepatitis (NASH) 2017 Market Insights, Epidemiology and Forecast – 2027
WiseGuyReports.com adds “Nonalcoholic Steatohepatitis (NASH) Market 2017 Global Analysis Research Report Forecasting to 2027”reports to its database.
PUNE, INDIA, November 8, 2017 /EINPresswire.com/ -- Nonalcoholic Steatohepatitis (NASH) Market1:Executive Summary
DelveInsight’s ‘Nonalcoholic Steatohepatitis (NASH)- Market Insights, Epidemiology and Market Forecast-2027’ report provides a disease overview of the Nonalcoholic Steatohepatitis (NASH) along with the epidemiology and the market scenario in the 7MM – United States, EU5 (Germany, France, Spain Italy , United Kingdom) and Japan.
The Report covers the therapeutics market revenue, treatment practice and Nonalcoholic Steatohepatitis (NASH) forecasted market share from 2017 to 2027 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Nonalcoholic Steatohepatitis (NASH) till 2027. Our epidemiology forecast covers the prevalent population as well as the diagnosed population having Nonalcoholic Steatohepatitis (NASH).
The report also covers the detailed market size forecast for 7MM. According to DelveInsight, it is estimated that the market size of Nonalcoholic Steatohepatitis (NASH) in 7MM shall increase and reach up to 49.25 Billion in 2027, with the compound annual growth rate (CAGR) of 23.0% for the period i.e., 2015-2027.
Request Sample Report @ https://www.wiseguyreports.com/sample-request/2477598-nonalcoholic-steatohepatitis-nash-market-insights-epidemiology-and-market-forecast-2027
Nonalcoholic Steatohepatitis (NASH) is a subtype of NAFLD (Nonalcoholic Fatty Liver Disease) that is characterized by accumulation of large amount of fat in the liver, along with inflammation and scarring. NASH is one of the most common liver related health problem and is considered to be strongly associated with insulin resistance, central obesity, reduced glucose tolerance, type 2 diabetes mellitus (T2DM), arterial hypertension, and hypertriglyceridemia. The condition can further progress to cirrhosis, liver failure and rarely liver cancer.
Key Coverage and Benefits:
The report will help in developing business strategies by understanding the trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) market.
Organize sales and marketing efforts by identifying the best opportunities for Nonalcoholic Steatohepatitis (NASH) in US, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future market competition in the global Nonalcoholic Steatohepatitis (NASH) market and Insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.
For further information on this report, visit - https://www.wiseguyreports.com/enquiry/2477598-nonalcoholic-steatohepatitis-nash-market-insights-epidemiology-and-market-forecast-2027
Table of Contents
1. Report Introduction
2. Non-Alcoholic Steatohepatitis Market Overview at a Glance
3. Total Market Share Distribution of Non-Alcoholic Steatohepatitis for 7 MM in 2016
4. Total Market Share Distribution of Non-Alcoholic Steatohepatitis for 7 MM in 2027
5. Non-Alcoholic Steatohepatitis
5.1. Introduction
5.2. Types
5.3. Classification of NASH: Stages of Fibrosis
5.4. Causes
5.5. Pathophysiology
5.6. Symptoms
5.7. Diagnosis
6. Epidemiology and Patient Population
7. Key Points:
8. Population and Forecast Parameters
9. Prevalent Population of NASH in 7MM
10. Region-Wise Prevalent Population of NASH
11. Diagnosed Population of NASH in 7MM
12. Region-Wise Diagnosed Population of NASH
13. Treatment Algorithm
14. American Association for the Study of Liver Diseases (AASLD) Current Recommendations for NAFLD/NASH
15. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
16. Guideline for NAFLD/NASH, by the Japanese Society of Gastroenterology (JSG) in cooperation with “The Japan Society of Hepatology”
17. Unmet Needs
18. Emerging Drugs
18.1. Phase-III Drugs Analysis
18.2. Phase-II Drugs Analysis
19. Emerging Therapies
19.1. Elafibranor(GFT505): GenfitPharma
19.1.1. Regulatory Milestones
19.1.2. Other development activities
19.1.3. Clinical Development
19.1.4. Ongoing Trials Information
19.1.5. Safety and Efficacy
19.1.6. Advantages and Disadvantages
19.1.7. Product Profile
19.2. Obeticholic Acid (OCA): Intercept Pharmaceuticals, Inc.
19.2.1. Regulatory milestones
19.2.2. Other development activities
19.2.3. Clinical Development
19.2.4. Ongoing Trials Information
19.2.5. Safety and Efficacy
19.2.6. Advantages and Disadvantages
19.2.7. Product Profile
19.3. Selonsertib (Ask-1 Inhibitor): Gilead Sciences, Inc.
19.3.1. Other development activities
19.3.2. Clinical Development
19.3.3. Clinical Pipeline Activity
19.3.4. Safety and Efficacy
19.3.5. Advantages and Disadvantages
19.3.6. Product Profile
19.4. Cenicriviroc (CVC): Allergan/Tobira Therapeutics
19.4.1. Regulatory milestones
19.4.2. Other development activities
19.4.3. Clinical Development
19.4.4. Ongoing Trials Information
19.4.5. Safety and Efficacy
19.4.6. Advantages and Disadvantages
19.4.7. Product Profile
19.5. NGM282: NGM Biopharmacueticals, Inc.
19.5.1. Other development activities
19.5.2. Clinical Development
19.5.3. Ongoing Trials Information
19.5.4. Safety and Efficacy
19.5.5. Advantages and Disadvantages
19.5.6. Product Profile
19.6. BMS-986036:Bristol-Myers Squibb Company
19.6.1. Other development activities
19.6.2. Clinical Development
19.6.3. Ongoing trials information
19.6.4. Safety and Efficacy
19.6.5. Advantages and Disadvantages
19.6.6. Product Profile
19.7. Emricasan: Conatus Pharmaceuticals Inc.
19.7.1. Regulatory milestones
19.7.2. Other development activities
19.7.3. Clinical Development
19.7.4. Ongoing trials information
19.7.5. Safety and Efficacy
19.7.6. Product Profile
19.8. IVA337: Inventiva Pharma
19.8.1. Regulatory milestones
19.8.2. Clinical Development
19.8.3. Ongoing trial information
19.8.4. Safety and Efficacy
19.8.5. Product Profile
20. Nonalcoholic Steatohepatitis (NASH): Country-Wise Market Analysis
21. United States
22. Europe
23. Germany
24. France
25. Italy
26. Spain
27. United Kingdom
28. Japan
29. Market Drivers
30. Market Barriers
31. Appendix
32. Report Methodology
33. Consulting Services
Continuous…
Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2477527
Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here
1 https://www.wiseguyreports.com/sample-request/2477598-nonalcoholic-steatohepatitis-nash-market-insights-epidemiology-and-market-forecast-2027